Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.

Abstract

BACKGROUND:

Acute venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is traditionally managed with a short course of parenteral anticoagulation followed by 3-6 months of a vitamin-K antagonist. Non-vitamin K oral anticoagulants (NOACs) do not require routine monitoring and dose adjustment, thus potentially provide an alternative treatment option.

METHODS AND RESULTS:

Because of the lack of head-to-head clinical studies, an indirect comparison was conducted of dabigatran etexilate and rivaroxaban based on the respective phase III clinical trial. The derived relative safety and efficacy estimates were used to evaluate the cost-utility of dabigatran compared with rivaroxaban in the treatment and secondary prevention of VTE. The results of the indirect comparison showed no significant difference between dabigatran and rivaroxaban in avoiding recurrent VTE following index PE, index DVT, or DVT/PE combined, in treatment and extended anticoagulation. Dabigatran has significantly less major or clinically relevant bleeds (MCRBE) compared to rivaroxaban in treatment after index DVT and treatment after DVT or PE combined, but was not significantly different from rivaroxaban after index PE or in extended anticoagulation. In cost-utility deterministic analyses, dabigatran was projected dominant in all analyzed settings, given its marginally lower total cost and marginally higher QALYs gained compared to rivaroxaban. Probabilistic analyses results showed a high likelihood of dabigatran being considered good value for money in the UK, in treatment and in secondary prevention of VTE.

CONCLUSION:

The cost-effectiveness evaluations showed that dabigatran can be considered the dominant treatment strategy compared to rivaroxaban in the patients' sub-groups considered, given the projected marginally higher clinical benefits and lower treatment costs.

• Authors: Anamaria Vera Jugrin, Volker Hösel, Anastasia Ustyugova, Maria De Francesco, Mark Lamotte, Tom Sunderland
• Journal: Journal of medical economics (J Med Econ) Vol. 19 Issue 1 Pg. 1-10 ( 2016) ISSN: 1941-837X [Electronic] England
• PMID: 26390231 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anticoagulants
• Warfarin
• Rivaroxaban
• Dabigatran

Topics

• Anticoagulants (economics, therapeutic use)
• Cost-Benefit Analysis
• Dabigatran (economics, therapeutic use)
• Double-Blind Method
• Female
• Health Services (economics, statistics & numerical data)
• Hemorrhage (chemically induced)
• Humans
• Male
• Middle Aged
• Models, Econometric
• Pulmonary Embolism (drug therapy)
• Quality-Adjusted Life Years
• Rivaroxaban (economics, therapeutic use)
• Venous Thromboembolism (drug therapy)
• Venous Thrombosis (drug therapy)
• Warfarin (therapeutic use)